A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health.
“We’ve developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations.
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.”
The Latest on: Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer immunotherapy
- Cancer Immunotherapy Market to Garner US$ 180,137.7 Mn, with a CAGR of 9.9% by 2028 | Novartis AG, Merck & Co. Inc., Roche, Eli Lilly and Companyon November 17, 2022 at 11:02 pm
The market for cancer immunotherapy was estimated at US$ 93,407.0 million in 2021 and is anticipated to grow at a CAGR of 9.9% from 2022 to 2028 to reach US$ 180,137.7 million. As research and ...
- Newfound cancer cell biology suggests which patients will respond to immunotherapyon November 17, 2022 at 11:53 am
Patients with head and neck cancer who have more genetic material on chromosome 9 in their cancer cells survive three times longer after receiving immunotherapy than those with less genetic material ...
- Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapyon November 17, 2022 at 8:03 am
Evaxion Biotech A/S (NASDAQ: EVAX) has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, ...
- Immunotherapy-Related Myocarditis Linked to T Cells Targeting Cardiac-Specific Antigenon November 17, 2022 at 5:05 am
Myocarditis—inflammation of the heart muscle—is a rare, but potentially fatal complication of immune checkpoint inhibitor (ICI) cancer immunotherapy. Researchers at Vanderbilt-Ingram Cancer Center ...
- Machine learning can help predict patient response to cancer immunotherapyon November 17, 2022 at 4:59 am
Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at the Johns Hopkins Kimmel ...
- Researchers develop promising new cancer therapyon November 16, 2022 at 7:43 am
Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system's T cells to attack tumor cells. Their introduction a decade ago marked a major advance in cancer therapy, ...
- Somatic Cell Copy Number Changes in HNSC Cancer Predict Immunotherapy Responseon November 15, 2022 at 5:05 am
Cancer cells hide from the system by hijacking checkpoint sensors that keep the immune cells from attacking normal cells. Checkpoint inhibitor immunotherapy uses proteins called antibodies to make ...
- Newfound cancer cell biology suggests which patients will respond to immunotherapyon November 14, 2022 at 12:00 pm
Patients with head and neck cancer who have more genetic material on chromosome 9 in their cancer cells survive three times longer after receiving immunotherapy than those with less genetic ...
- Capitalizing on cancer immunotherapy techniques to develop a potential variant-proof treatment for COVID-19on November 10, 2022 at 4:00 pm
The first immunotherapy method focuses on the spike ... nonprofit biomedical research institution with a National Cancer Institute-designated Cancer Center and nearly 3,000 employees in locations ...
via Bing News